Sicca syndrome/Sjögren’s disease associated with cancer immunotherapy: a narrative review on clinical presentation, biomarkers, and management
Expert Review of Clinical Immunology,
Journal Year:
2024,
Volume and Issue:
20(10), P. 1149 - 1167
Published: June 21, 2024
Almost
one-quarter
of
immune
checkpoint
inhibitor
(ICI)
recipients
experience
sicca
syndrome,
while
Sjögren's
disease
(SjD)
is
estimated
at
0.3-2.5%,
possibly
underreported.
Language: Английский
Targeted Therapy for Severe Sjogren’s Syndrome: A Focus on Mesenchymal Stem Cells
International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(24), P. 13712 - 13712
Published: Dec. 22, 2024
Primary
Sjögren’s
syndrome
(pSS)
is
an
autoimmune
disease
characterized
by
the
infiltration
of
lymphocytes
on
salivary
and
lacrimal
glands,
resulting
in
their
dysfunction.
Patients
suffering
from
severe
pSS
have
increased
risk
developing
multi-organ
dysfunction
due
to
development
systemic
inflammatory
response,
which
results
immune
cell-driven
injury
lungs,
kidneys,
liver,
brain.
Therapeutic
agents
that
are
used
for
treatment
encounter
various
limitations
challenges
can
impact
effectiveness.
Accordingly,
there
a
need
targeted,
personalized
therapy
could
address
underlying
detrimental
response
while
minimizing
side
effects.
Results
obtained
large
number
recently
published
studies
demonstrated
therapeutic
efficacy
mesenchymal
stem
cells
(MSCs)
pSS.
MSCs,
juxtacrine
paracrine
manner,
suppressed
generation
Th1
Th17
lymphocytes,
induced
expansion
immunosuppressive
cells,
impaired
cross-talk
between
auto-reactive
T
B
prevented
synthesis
secretion
auto-antibodies.
Additionally,
MSC-derived
growth
trophic
factors
promoted
survival
apoptosis
injured
inflamed
thereby
enhancing
repair
regeneration.
In
this
review
article,
we
summarized
current
knowledge
about
molecular
mechanisms
responsible
beneficial
effects
MSCs
suppression
exocrine
glands
vital
organs,
paving
way
better
understanding
potential
targeted
Language: Английский
Tear Proteomics in Children and Adolescents with Type 1 Diabetes: A Promising Approach to Biomarker Identification of Diabetes Pathogenesis and Complications
International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(18), P. 9994 - 9994
Published: Sept. 17, 2024
The
aim
of
the
current
study
was
to
investigate
tear
proteome
in
children
and
adolescents
with
type
1
diabetes
(T1D)
compared
healthy
controls,
identify
differences
T1D
depending
on
different
characteristics
disease.
Fifty-six
at
least
one
year
after
diagnosis,
aged
6–17
years
old,
fifty-six
age-
sex-matched
controls
were
enrolled
this
cross-sectional
study.
proteomic
analysis
based
liquid
chromatography
tandem
mass
spectrometry
(LC-MS/MS)
enabling
identification
quantification
protein
content
via
Data-Independent
Acquisition
by
Neural
Networks
(DIA-NN).
Data
are
available
ProteomeXchange
identifier
PXD052994.
In
total,
3302
proteins
identified
from
samples.
Two
hundred
thirty-nine
differentially
expressed
controls.
Most
them
involved
immune
response,
tissue
homeostasis
inflammation.
presence
diabetic
ketoacidosis
diagnosis
level
glycemic
control
influenced
proteome.
Tear
proteomics
revealed
a
pattern
offering
insights
deregulated
biological
processes
underlying
pathogenesis
T1D.
Differences
within
group
could
unravel
biomarkers
for
early
detection
long-term
complications
Language: Английский
Olho seco
Revista Paulista de Reumatologia,
Journal Year:
2024,
Volume and Issue:
23(1), P. 19 - 23
Published: March 31, 2024
O
diagnóstico
da
doença
de
Sjögren
(DSj)
em
pacientes
com
xeroftalmia
envolve
uma
avaliação
específica
que
inclui
questionários
para
sintomas
olho
seco,
testes
oculares,
pesquisa
autoanticorpos
e
biópsia.
Os
desafios
a
definição
etiológica
do
seco
decorrem
sobreposição
clínicos
outras
condições
clínicas
sub-referenciamento
complementar
DSj.
Não
há
um
único
teste
permita
diferenciar
o
associado
à
DSj
somente
combinação
sintomas,
exame
ocular
dirigido,
biomarcadores
séricos
pode
ajudar,
partir
abrangente
oftalmologista
experiente.
tratamento
indivíduos
é
complexo
evolução.
Embora
terapêutica
atual
melhora
escores
ceratite,
medidos
pela
coloração
córnea,
redução
inflamação
superfície
ocular,
desafio
desenvolvimento
tratamentos
eficazes
além
dos
colírios
lubrificantes.
Pesquisas
futuras
devem
se
concentrar
métodos
mais
precisos
estratégias
terapêuticas
personalizadas
melhorar
qualidade
vida
portadores
prevenção
complicações.
Unitermos:
seco;
Schirmer;
tacrolimus;
soro
autólogo;
ômega
3.